News Sentiment

TVRD sentiment intelligence

Tvardi Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 43 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.28 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 35

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+62.4% over one week, +24.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Tvardi Therapeutics Company Profile & Introduction

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 62.4% Price confirming higher
Trend fit Trend inactive 24.2% over four weeks
Fair value -85.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 34
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 35
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
GlobeNewswire 6
Market source 5
Moomoo 3
Quartr 3
Benzinga 2
Quiver Quantitative 2
Stock Titan 2
TradingView 2

Event Lens

What the news is about

Classified themes
Market update 20
Earnings 12
Deals and strategy 8
Analyst action 2
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 43
Associated Press Direct company coverage

Tvardi: Q1 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
08 May 2026 11:11
Source
Associated Press
Stock Titan Direct company coverage

Tvardi Therapeutics (NASDAQ: TVRD) outlines 2026 votes on board, pay and auditors

Tvardi Therapeutics (NASDAQ: TVRD) has released proxy materials for its 2026 virtual annual meeting on June 9, 2026, where shareholders will vote on the election of three Class II directors, a non-binding advisory "say-on-pay" resolution for executive compensation, and the freque

Tone
Neutral 50/100
Event
Market update
Published
24 Apr 2026 16:09
Source
Stock Titan
GlobeNewswire Direct company coverage

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Tvardi Therapeutics announced its financial and operating results for the fourth quarter and full-year ended December 31, 2025, and provided a business update. Key milestones include anticipated topline data from its next-generation STAT3 inhibitor, TTI-109, in Q2 2026, and from

Tone
Positive 66/100
Event
Earnings
Published
31 Mar 2026 16:01
Source
GlobeNewswire
Intellectia AI Direct company coverage

CARA Stock News Today | Earnings, Events & Price Alerts

Cara Therapeutics (CARA) has been actively involved in corporate actions, including merger agreements and reverse stock splits. The company is set to merge with Tvardi Therapeutics, with the combined entity operating as Tvardi Therapeutics under the symbol "TVRD" after a 1-for-3

Tone
Positive 64/100
Event
Deals and strategy
Published
28 Feb 2026 09:52
Source
Intellectia AI
Defense World Direct company coverage

Barclays Begins Coverage on Tvardi Therapeutics (NASDAQ:TVRD) - Defense World

Barclays has initiated coverage on Tvardi Therapeutics (NASDAQ:TVRD). Other analysts, including Piper Sandler, BTIG Research, and Cantor Fitzgerald, have recently updated their ratings and price targets for the stock. The article also notes recent institutional investor activity

Tone
Neutral 50/100
Event
Market update
Published
15 Oct 2025 06:19
Source
Defense World